In a case where asthma developed following pembrolizumab administration, increased levels of IL-5 cytokine in the blood were observed, suggesting a possible link between PD-1 inhibitor administration and the onset of asthma through IL-5 cytokine production [74]. This evidence concerns the gene IL5 and asthma.